ONO PHARMA USA

ONO's clinical trials in oncology are growing under experienced leaders, like VP of Medical Oncology, Dr.?Howard Fingert, MD, MA, FACP.?? ?? With more than three decades of biopharmaceutical industry experience, Howard developed new treatments for leukemia, lymphoma, and solid tumors, many of which are now global standards of care.??? ?? Building on ONO’s 300-year history and growing partnerships with academia, biopharma, government research and patient-advocacy communities, Howard?is committed to expanding our?oncology pipeline to?additional indications and underserved populations.??? ?? ONO’s and Howard's mission are one and the same: Bring new treatment options to patients who need them. With his great?leadership, we're excited about what the future holds.?

What could make a friendly step challenge with colleagues even better? For ONO, it’s supporting an important cause. Thousands of team members from our offices across the world have joined Ono’s annual Walking Campaign, where we compete to see who can log the most steps throughout the months of October and November. It’s all for a good cause: raising funds to support the Union for International Cancer Control. We strongly believe in the UICC’s mission to fight cancer through prevention, access to care, advocacy, and more, and we’re very proud to support it. So who will win the challenge? Does it really matter? When we walk to get healthier and support a great cause, everyone is a winner. (But stay tuned: we’ll still announce the results later!)

People living with multiple system atrophy (MSA) need treatment options. We want to help address that unmet need.? MSA is a rare neurological disease that impairs different parts of movement, including coordination, balance, and speech, as well as automatic functions, like blood pressure regulation and bladder control.? Our clinical development colleagues recently attended the International Parkinson and Movement Disorder Society conference and shared information about our Phase 2 MSA clinical trial in the U.S. and Japan. The study is evaluating an investigational treatment for MSA. Currently, there is no FDA-approved therapy for MSA. ? ONO is recruiting participants at healthcare centers across the country.?Learn more at https://lnkd.in/gfMGJadg

Helping patients can take many different forms.?? ?? For our Associate Medical Director,?Dr. Aditi Korlimarla, designing clinical trials at ONO PHARMA USA provides an opportunity to serve patients in a unique way.?? ?? While her previous work as a physician was rewarding, Aditi's experience in research has taught her the importance of drug development in patient care.?? ?? Aditi says designing clinical studies for several different diseases helps her to evaluate unmet needs in the community, advocate patient safety during drug development stages, and create a more lasting impact on patients’ lives.?? ?? Hear more about how working at ONO supports Aditi’s goal of providing therapeutic options to the people who most need them.??

Developing one-of-a-kind treatments requires a team of exceptionally talented people.? Our Vice President of Medical Affairs,?Thomas Lechner MSc PhD, is one of them. With over 20 years of global experience in the pharmaceutical industry, Thomas is making an impact and shaping the future of ONO PHARMA USA. As our?head of U.S. medical affairs, Thomas is building his team's infrastructure?and driving medical strategy for our late-stage pipeline. He engages key opinion leaders and clinical investigators as we build out our clinical trial program across the U.S. In addition, Thomas also strives to deepen company culture and?keep?our teams up to date and poised for growth. Thank you, Thomas, for keeping our medical strategy and team culture at all-time highs!

For our Senior Director of Market Access,?Mehul Jhaveri,?working at ONO PHARMA USA is the best of two worlds:? ONO's?300-year legacy of groundbreaking research paired with our small but mighty team in Cambridge.? This combination sets the team up for success – and for bringing innovative medicines to patients. Hear more on Mehul's role and his commitment to advancing care.

Primary central nervous system lymphoma (PCNSL) is one of the rarest forms of lymphoma.? This aggressive?non-Hodgkin's?lymphoma accounts for?3-4% of all?primary?brain tumors. Being diagnosed with?PCNSL can be devastating, and the disease itself?can be fatal. While chemotherapy and radiation can increase chances for?survival, sadly there is currently no FDA-approved therapy specifically for PCNSL. We want to change that. This Leukemia and Lymphoma Awareness Month, we're thinking about all those affected by blood cancers, and are?committed to advancing care for people living with PCNSL.

We're ready to make breakthroughs.?? ? After nearly three decades at ONO, Kunihiko Ito, President and CEO of ONO PHARMA USA, is as energized as ever for the company's continued growth.?? ? This enthusiasm is echoed by our entire staff in Cambridge. Our growing team and expanding clinical trial program gets us excited to come to work each day.?? ? For Team ONO, we're driven by a single purpose: advancing breakthroughs in science to make a difference in patients' lives.?

Our Cambridge office benefits from the energy of our Japanese colleagues, who become an integral part of the ONO team. They come to the U.S. with unique perspectives and a shared determination to fight disease and pain. As they work to expand ONO's U.S. presence, they're also immersing themselves in American culture. From discovering hidden gems while traveling to forging unbreakable bonds, their journey here has been one of growth and connection.?? ? But as with all good things, the day inevitably comes when they must return home. Saying goodbye to these colleagues-turned-friends tugs at our hearts. We've laughed together, overcome challenges side by side, and created memories that will endure. Though their departure leaves a void, it's tempered by the gratitude we feel for having shared in their adventure. They made an impact in our lives and on the progress we have?made toward our mission.?

Did you know lawyers?are?key to scientific innovation??? ?? It's true: legal counsel helps us stay compliant as we expand our work in the U.S.??? ?? Luckily, we have the best and the brightest General Counsel around.?Daniel Moynihan joined ONO in 2022,?bringing with him 25 years of expertise in building and?revamping compliance programs across leading biopharma organizations.??? ?? Dan's wide-ranging knowledge?makes him a key advisor to?senior leadership – and critical guide to all our teams through the ever-changing regulatory landscape.??? ?? Thank you, Dan, for your sage counsel as we challenge the unknown!??